Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Rhian E Davies , J Dawn Abbott Added: 3 years ago
Percutaneous Coronary Intervention for Clinical Syndromes Stable Angina The primary benefit of percutaneous coronary intervention (PCI) over medical therapy in patients with stable angina is the improved quality of life. The PCI in stable angina (ORBITA) trial was the first sham-controlled trial of PCI where 200 medically optimized patients with single vessel disease were randomized to PCI or… View more

Intervention
FAME3: PCI Guided by FFR Didn't Meet Noninferiority for 1Y Outcomes Compared to CABG
Author(s): William Fearon Added: 2 years ago
In this short interview, Dr William F Fearon (Stanford University School of Medicine, US) discusses the findings from the FAME3 trial. This multicenter, international, randomized, controlled noninferiority trial investigated whether fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease (CAD) will result in similar… View more

Intervention
Angela Hoye
Job title: Consultant Cardiologist
Angela Hoye is an Interventional Cardiologist at Castle Hill Hospital, Hull and a Senior Lecturer in Cardiology at the Centre for Cardiovascular and Metabolic Research, Hull York Medical School. She completed cardiology training in East Yorkshire, UK and has a speciality interest in coronary intervention. She worked for two years at the Thoraxcenter, Rotterdam between 2002 and 2004, and… View more
A Pieter Kappetein
Job title: Consultant Cardiothoracic Surgeon, Professor and Chair of the residency program
Dr. Pieter Kappetein, MD, PhD, is a Consultant Cardiothoracic Surgeon, Professor and Chair of the residency program at the Thoraxcenter at the Erasmus Medical Centre in Rotterdam, The Netherlands. He is board certified in Cardiothoracic Surgery. His specialty is cardiothoracic surgery. He is Secretary General of the European Association for Cardio-thoracic Surgery, President of CTSnet and member… View more
TCT Connect 2020: The XIENCE 90/28 Trials
Author(s): Roxana Mehran Added: 3 years ago
Dr Roxana Mehran (Icahn School of Medicine at Mount Sinai, New York, NY, US) discusses the landmark trialXIENCE 90/28. XIENCE 90/28 evaluated the safety of 3-month and 1 month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family of coronary drug-eluting stents. Questions 1. What is the… View more

Anticoagulation

Intervention
CRT 2019: Dr Jihad Mustapha - SAVAL Trial
Author(s): Jihad Mustapha Added: 5 years ago
Dr Jihad Mustapha (Advanced Cardiac &Vascular Centers, Grand Rapids, US) discusses the SAVAL trial - Next steps in drug-eluting stents for BTK intervention. Filmed on site by Radcliffe Cardiology. Questions: 1. Why was the SAVAL trial needed? (00:10) 2. What was the study design? (00:42) 3. What is novel about this particular stent? (01:24) 4. If this trial is positive, how might this… View more

Intervention
TWILIGHT-Stent: Ticagrelor Monotherapy According to Stent Type
Author(s): George D Dangas Added: 2 years ago
Dr George Dangas (Mount Sinai Hospital, New York, NY, US) discusses the results of the TWILIGHT-Stent trial, presented at ESC 2021. This study examined the incidence of ischemic and bleeding events in patients treated with contemporary drug-eluting stents over 3-15 months. This trial also examined ticagrelor monotherapy vs ticagrelor with aspirin. Questions: 1. What were the main aims of… View more

Anticoagulation

Intervention
Feasibility, Safety, and Clinical Performance of Self-apposing Stents for Left Main Stenosis
Author(s): Krzysztof Pujdak , Jan Kähler , Marc Werner Added: 3 years ago
Significant stenosis of the left main (LM) coronary artery is observed in 7% of coronary angiographies.1 Coronary artery bypass grafting has traditionally been the treatment of choice. In recent years, percutaneous coronary intervention (PCI) has evolved as an alternative, especially for low and intermediate SYNTAX score patients.2 However, during PCI of bifurcation lesions, approximately 50% of… View more

Intervention
Renu Virmani
Research Area(s) / Expertise: Job title: President and Medical Director
Personal History Dr Renu Virmani was born in 1943 in Pakistan. Her father was an industrialist of Delhi and Amritsar, India.2 As the youngest girl in a family of ten children, Dr Virmani was always driven to stand out and excel. Her aunt, who was a neurologist, was instrumental in forging her ambitions to pursue medicine. “I admired her and she showed me that women can do whatever they want… View more
Author(s): Donald E Cutlip Added: 3 years ago
Stent thrombosis has been recognized as a serious complication of coronary stent placement since the procedure was first reported in the 1980s.1 Subsequent aggressive peri-procedural anti-thrombotic strategies with inpatient transition to warfarin reduced the risk to about 3.5 % for subacute (30-day) stent thrombosis,2,3 a rate that would be unacceptable by current standards and did not account… View more

Prevention & Chronic Conditions

Intervention